NCT02702518View on ClinicalTrials.gov

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions
Ocular Graft vs Host DiseaseDry Eye
Interventions
DRUG

rhDNase I

rhDNase I, 0.1% eye drops 4 times a day for 8 weeks

DRUG

Vehicle

Drug vehicle 4 times a day for 8 weeks

Trial Locations (2)

60612

Translational Clinic of Corneal Neurobiology laboratory, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago

University of Illinois Eye and Ear Infirmary, Chicago

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Eye Institute (NEI)

NIH

lead

University of Illinois at Chicago

OTHER

NCT02702518 - rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease | Biotech Hunter | Biotech Hunter